2,000 Shares in Stryker Corporation $SYK Acquired by Syntax Research Inc.

Syntax Research Inc. acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,000 shares of the medical technology company’s stock, valued at approximately $657,000.

Several other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares during the period. State Street Corp lifted its stake in Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares in the last quarter. Geode Capital Management LLC boosted its position in Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after acquiring an additional 69,851 shares during the period. Wellington Management Group LLP grew its stake in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Trading Down 0.5%

Shares of NYSE SYK opened at $313.38 on Thursday. The business has a 50 day simple moving average of $309.89 and a 200 day simple moving average of $339.15. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The stock has a market cap of $120.14 billion, a price-to-earnings ratio of 36.27, a PEG ratio of 2.02 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group reduced their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Evercore set a $355.00 price objective on shares of Stryker in a research report on Friday, May 1st. Leerink Partners dropped their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.